Uday Popat

16.8k total citations
396 papers, 6.6k citations indexed

About

Uday Popat is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Uday Popat has authored 396 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 286 papers in Hematology, 108 papers in Genetics and 106 papers in Oncology. Recurrent topics in Uday Popat's work include Hematopoietic Stem Cell Transplantation (137 papers), Acute Myeloid Leukemia Research (125 papers) and Multiple Myeloma Research and Treatments (74 papers). Uday Popat is often cited by papers focused on Hematopoietic Stem Cell Transplantation (137 papers), Acute Myeloid Leukemia Research (125 papers) and Multiple Myeloma Research and Treatments (74 papers). Uday Popat collaborates with scholars based in United States, Canada and United Kingdom. Uday Popat's co-authors include Richard E. Champlin, Chitra Hosing, Gabriela Rondón, Partow Kebriaei, Muzaffar H. Qazilbash, Elizabeth J. Shpall, Rima M. Saliba, Amin M. Alousi, Sergio Giralt and Betül Oran and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Uday Popat

379 papers receiving 6.5k citations

Peers

Countries citing papers authored by Uday Popat

Since Specialization

Citations

This map shows the geographic impact of Uday Popat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uday Popat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uday Popat more than expected).

Fields of papers citing papers by Uday Popat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uday Popat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uday Popat. The network helps show where Uday Popat may publish in the future.

Co-authorship network of co-authors of Uday Popat

This figure shows the co-authorship network connecting the top 25 collaborators of Uday Popat. A scholar is included among the top collaborators of Uday Popat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uday Popat. Uday Popat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis 2025 ·Blood Advances ·Yosra Aljawai, Jeremy Ramdial, Gabriela Rondón, (unknown), Partow Kebriaei, Uday Popat, Betül Oran, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta	2
2	TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation 2025 ·Blood Advances ·Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal‐Shamanna, (unknown), Jeremy Ramdial, George L. Chen, Tapan M. Kadia, Nicholas J. Short, Naval Daver, Hagop M. Kantarjian, (unknown), Partow Kebriaei, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall, Betül Oran	4
3	Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia 2024 ·Blood ·(unknown), (unknown), Celina Ledesma, Nitin Jain, Priti Tewari, Issa F. Khouri, Amanda Olson, Gheath Alatrash, Nicholas J. Short, Elias Jabbour, Katy Rezvani, Amin M. Alousi, Uday Popat, Richard Champlin, Elizabeth J. Shpall, (unknown)	1
4	Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML 2024 ·Blood ·Betül Oran, David Marin, Qaiser Bashir, Sairah Ahmed, Amanda Olson, Uday Popat, Partow Kebriaei, Elizabeth J. Shpall, Vinay Jain, R. Champlin	1
5	Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation 2024 ·American Journal of Hematology ·Jayastu Senapati, Hagop M. Kantarjian, Fadi Haddad, Nicholas J. Short, Gautam Borthakur, Rashmi Kanagal‐Shamanna, Guilin Tang, Elias Jabbour, Courtney D. DiNardo, Naval Daver, Guillermo Montalban‐Bravo, (unknown), Amin Alousi, (unknown), Uday Popat, Guillermo Garcia‐Manero, Farhad Ravandi, Tapan M. Kadia	3
6	Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Oren Pasvolsky, Rima M. Saliba, (unknown), (unknown), (unknown), Sairah Ahmed, Musa Yılmaz, Naval Daver, Farhad Ravandi, Courtney D. DiNardo, Nicholas J. Short, Tapan M. Kadia, Gheath Alatrash, May Daher, (unknown), Uday Popat, Richard Champlin, Elizabeth J. Shpall, Betül Oran	2
7	A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. 2024 ·Journal of Clinical Oncology ·Monzr M. Al Malki, Alla Keyzner, Hyung C. Suh, Uday Popat, Saar Gill, (unknown), Melhem Solh, Lohith Gowda, Erica L. Buonomo, Yun Wang, J. A. H. Murray, Gavin MacBeath, Débora Barton, Shrikanta Chattopadhyay, Ran Reshef	1
8	Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease 2024 ·Bone Marrow Transplantation ·(unknown), Amin M. Alousi, Jin S. Im, LaQuisa Hill, (unknown), Uday Popat, Chitra Hosing, Partow Kebriaei, Amanda Olson, Rohtesh S. Mehta, George Chen, Muzaffar H. Qazilbash, Elizabeth J. Shpall, Richard E. Champlin, Rima M. Saliba	1
9	Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning 2023 ·Transplantation and Cellular Therapy ·Jacinth Joseph, Samer A. Srour, Denái R. Milton, Jeremy Ramdial, Neeraj Saini, Amanda Olson, Qaiser Bashir, Betül Oran, Amin M. Alousi, Chitra Hosing, Muzaffar H. Qazilbash, Partow Kebriaei, Elizabeth J. Shpall, Richard E. Champlin, Uday Popat	3
10	Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation 2023 ·Blood Advances ·Nicholas J. Short, (unknown), Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Betül Oran, Gheath Alatrash, Rohtesh S. Mehta, Elias Jabbour, Musa Yılmaz, Ghayas C. Issa, Abhishek Maiti, Richard E. Champlin, Hagop M. Kantarjian, Elizabeth J. Shpall, Uday Popat	13
11	Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant 2023 ·Bone Marrow Transplantation ·Taha Al‐Juhaishi, Yingjun Wang, Denái R. Milton, Zijun Y. Xu‐Monette, Elias Jabbour, May Daher, Jin S. Im, Qaiser Bashir, Swaminathan P. Iyer, David Marín, Amanda Olson, Uday Popat, Muzaffar H. Qazilbash, Gabriela Rondón, Alison Gulbis, Richard E. Champlin, Ken H. Young, Issa F. Khouri	3
12	Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Kris M. Mahadeo, Uday Popat, Elizabeth J. Shpall, Sajad Khazal	3
13	Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era 2021 ·British Journal of Haematology ·Mithun Vinod Shah, Rima M. Saliba, Ankur Varma, Stefan O. Ciurea, Betül Oran, Amanda Olson, Prithviraj Bose, Qaiser Bashir, Lucia Masárová, Amin M. Alousi, Samer A. Srour, Rohtesh S. Mehta, Naval Daver, Naveen Pemmaraju, Srđan Verstovšek, Richard E. Champlin, Uday Popat	8
14	Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy 2021 ·Cancer ·Sangeetha Venugopal, Mahran Shoukier, Marina Konopleva, Courtney D. DiNardo, Farhad Ravandi, Nicholas J. Short, Michael Andreeff, Gautam Borthakur, Naval Daver, Naveen Pemmaraju, Koji Sasaki, Guillermo Montalban‐Bravo, Kayleigh Marx, Sherry Pierce, Uday Popat, Elizabeth J. Shpall, Rashmi Kanagal‐Shamanna, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Tapan M. Kadia	43
15	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients 2020 ·Blood Advances ·Betül Oran, Marcos de Lima, Guillermo Garcia‐Manero, Peter F. Thall, Ruitao Lin, Uday Popat, Amin M. Alousi, Chitra Hosing, Sergio Giralt, Gabriela Rondón, (unknown), Richard E. Champlin	132
16	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors 2020 ·Cancer ·Betül Oran, Guillermo Garcia‐Manero, Rima M. Saliba, Mansour Alfayez, Gheath Alatrash, Stefan O. Ciurea, Elias Jabbour, Rohtesh S. Mehta, Uday Popat, Farhad Ravandi, Amin M. Alousi, Tapan M. Kadia, Marina Konopleva, Courtney D. DiNardo, Katy Rezvani, Elizabeth J. Shpall, Padmanee Sharma, Hagop M. Kantarjian, Richard E. Champlin, Naval Daver	31
17	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens 2019 ·Biology of Blood and Marrow Transplantation ·(unknown), Paul Lin, Rima M. Saliba, Uday Popat, Qaiser Bashir, Nina Shah, Krina K. Patel, Simrit Parmar, Partow Kebriaei, Chitra Hosing, Stefan O. Ciurea, Börje S. Andersson, Elizabeth J. Shpall, Richard E. Champlin, Samer A. Srour, Muzaffar H. Qazilbash	10
18	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia 2018 ·Biology of Blood and Marrow Transplantation ·(unknown), Katayoun Rezvani, Betül Oran, Rohtesh S. Mehta, Gabriela Rondón, Partow Kebriaei, Uday Popat, Yago Nieto, Chitra Hosing, Muzaffar H. Qazilbash, Issa F. Khouri, Elizabeth J. Shpall, Richard E. Champlin, David Marín	14
19	Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation 2017 ·Blood ·Stefan O. Ciurea, Doris Soebbing, Gabriela Rondón, Kai Cao, Gheath Alatrash, Sairah Ahmed, Uday Popat, Betül Oran, Qaiser Bashir, Partow Kebriaei, Indreshpal Kaur, Katayoun Rezvani, Elizabeth J. Shpall, Dean A. Lee, Richard E. Champlin	2
20	Ex Vivo Mesenchymal Precursor Cell–Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery 2017 ·Biology of Blood and Marrow Transplantation ·Rohtesh S. Mehta, Rima M. Saliba, Kai Cao, Indreshpal Kaur, Katy Rezvani, Julianne Chen, Amanda Olson, Simrit Parmar, Nina Shah, David Marín, Amin M. Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Richard E. Champlin, Marcos de Lima, Donna Skerrett, Elizabeth Burke, Elizabeth J. Shpall, Betül Oran	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact